Original article

Over-expression of $VEGF_{165}$ in the adipose tissue-derived stem cells via the lentiviral vector

SUN Xiang-zhou, LIU Gui-hua, WANG Zhuo-qing, ZHENG Fu-fu, BIAN Jun, HUANG Yan-ping, GAO Yong, ZHANG Ya-dong and DENG Chun-hua

Keywords: adipose tissue-derived stem cells; VEGF₁₆₅; lentivirus; over-expression

Background Many researchers studied the possibility of using stem cells as gene therapeutic vector. But few related reports on the adipose tissue-derived stem cells (ADSCs) are available. Therefore we intended to construct a lentiviral VEGF₁₆₅ expression vector and then infect the ADSCs to produce therapeutic seed cells.

Methods EHS1001-68950485313912 clone was mutated by PCR method to produce consensus fragment of VEGF₁₆₅ transcript (NM_001025368). Lentivirus was enveloped with pGC-FU, pHelper 1.0 and pHelper 2.0 plasmids in 293T cells. And then the ADSCs (multiplicity of infection=20) were transfected with the vectors after titer determination. Stable expression of VEGF₁₆₅ in ADSCs was confirmed by immunofluorescence staining, enzyme-linked immunosorbent assay (ELISA) and Western blotting analysis.

Results DNA sequencing and 293T transfection verified VEGF₁₆₅ was linked to the GFP fused vector. The virus titer is up to 2×10^8 determined by quantitative PCR. VEGF₁₆₅ transduced cells could show green fluorescence confirmed by immunofluorescence staining (almost 95%). ELISA analyses could detect out the density of VEGF was 850.86–1202.13 pg/ml (mean (923.00±31.22) pg/ml) in the supernatant of VEGF₁₆₅-transduced cells but not detected in the GFP-transduced cells (*P* <0.001) and the Western blotting analyses also confirmed VEGF₁₆₅ expression in VEGF₁₆₅-transduced cells.

Conclusions The VEGF₁₆₅ over-expression ADSCs were obtained and may be used as a cell therapeutic tool and may be applied for vascular regeneration, especially in the treatment of erectile dysfunction.

Chin Med J 2011;124(19):3093-3097

dipose tissue-derived stem cells (ADSCs) is a hotspot in stem cell therapeutic research recently, and multi-direction division of ADSCs is not affected by genetic modification and posses high proliferation rate, gene transduction susceptibility in vitro and long-term expression endurance. Hence it is the optimal gene therapeutic vectors.¹⁻⁶ Introduction of exogenous gene into stem cells is a vital procedure and relied on transduction vector on large extent. Adenovirus is acknowledged the most widely used media for high infect efficiency, but its deficiency is obvious: foreign genes are not integrated thus expression was transient and possessed cell toxicity. Letivirus, derived from HIV-1 virus overwhelmed adenovirus with its DNA integration mechanism triggered by Rev.⁷ In addition, coat protein of HSV dramatically alleviats immunogenicity.^{8,9} Lentiviral vectors introduce permanent and high expression in ADSCs to produce seed cells for damaged replace and long term treatment which overwhelm traditional therapeutic vectors by its endurance and efficiency.¹⁰

Vascular endothelial growth factor (VEGF) plays a critical role in vascular regenesis.¹¹⁻¹³ There are 5 subtypes of VEGF family and VEGF₁₆₅ is most active and widely distributed.¹¹ Nevertheless, for its short half life *in vivo*, drugs targeting at VEGF₁₆₅ are costliness and difficult to supply. Consequently, the clinical application of these drugs is considerable hindered. Attribute to the

development of molecular biology and genetic modification, marvelous progress in gene therapy improves the research in vascular regenesis of ischemia tissue.¹⁴ Additionally, the VEGF signaling system would work less well in diabetic erectile dysfunction (DMED) penile tissues as a result of the reduced expression of VEGF and its two receptors. The decrease of VEGF would lead to diminished endothelial production of NO and apoptosisrelated erectile tissue damage. The abnormalities of the VEGF signaling system in the penis may lead to the pathophysiology of diabetic erectile dysfunction (ED).¹⁵ And the forthcoming therapy was not fully effective.^{16,17}

Therefore, we herein intend to construct a lentiviral

DOI: 10.3760/cma.j.issn.0366-6999.2011.19.026 Department of Urology (Sun XZ, Liu GH, Zheng FF, Bian J, Huang YP, Gao Y, Zhang YD and Deng CH), Department of Scientific Research (Wang ZQ), First Affiliated Hospital of Sun Yet-sen University, Guangzhou, Guangdong 510080, China Correspondence to: Dr. SUN Xiang-zhou, Department of Urology, First Affiliated Hospital of Sun Yet-sen University, Guangzhou, Guangdong 510080, China (Email: sunxzh08@hotmail.com) This work was supported by grants from the National Natural Science Fundation of China (No. 30872571), National Youth Natural Science Fundation of China (No. 30901487), Natural Program of Guangdong Province (No. Science Fund 8451008901000774), Natural Science Fund Program of Guangdong Province (No. 07001628), Guangdong Province Science & Technology Project (No.2008GBCBC01250-014-149).

vector which can over-express $VEGF_{165}$ and transfect into rat ADSCs to obtain the therapeutic cells for potentially use in the DMED.

METHODS

Vectors and cells

EHS1001-6895048 5313912 clone was purchased from OPEN BIOSYSTEMS. Lentiviral expression vector pGC-FU, and envelope helper vectors pHelper 1.0 and pHelper 2.0 were produced by Genechem (Shanghai, China). *E. Coli* DH5a used in subclone, 293T cells used in envelope were conserved by Genechem. And we have previously described the isolation of rat ADSCs.¹⁸ Rat tissues were obtained with approval from our Institutional Animal Care and Use Committee.

Reagents

AgeI was purchased from New England Biolabs (USA), Taq polymerase and Sybr Green Master were products of TAKARA (Dalian, China) and plasmid extraction kit supplied by QIAGEN (USA). Lipo2000 kit used in tansfection and TRIZOL used in RNA extraction were produced by Invitrogen (USA). Antibodies were from Santa Cruz (Canada). Western blotting adopted ECL kit, Amersham (USA). M-MLV reverse transcriptase produced by Promega (USA) were used in qPCR analysis.

Vector construction

EHS1001-6895048 5313912 clone was mutated by PCR method to produce consensus fragment of VEGF₁₆₅ transcript (NM 001025368). Primers VEGF₁₆₅-N-R (5'-CTGACGGACAGACAGACAGACACCGCCCCA GCCCCAGCTACCACCTC-3'), VEGF₁₆₅-N-F(5'-CTG-ACGGACAGACAGACAGACACCGCCCCAGCCCC AGCTACCACCTC-3'), VEGF₁₆₅-N2-F (5'-CCTCCC-CGGCCGGCGGCGGAC-3'), VEGF₁₆₅-N2-R (5'-G-AGTCTGTGTTTTTGCAGGAACATTTACACGTC-3'), VEGF₁₆₅-C1-F (5'-GTTCCTGCAAAAACACAGACT-CGCGTTGCAAG-3'), were used to modify sequence and obtain 94 bp, 1002 bp and 105 bp fragments. The mixture of mutated fragments was amplified by VEGF₁₆₅-AgeI-F (5'-GAGGATCCCCGGGTACCGGTCGCCACCATGCT GACGGACAGACAGACAGAC-3') and VEGF₁₆₅-AgeI-R (5'-TCACCATGGTGGCGACCGGCCGCCTCGGCTTG TCACATC-3') by PCR to produce VEGF₁₆₅ cDNA clone. Entire fragment was digested by AgeI and link to pGCFU vector. DH5a transform ant was examined by PCR test using VEGF₁₆₅-SEQF (5'-GTGGTGAAGTTCATGGAT-G-3') and EGFP-N-R (5'-CGTCGCCGTCCAGCTCGA-CCAG-3'). Positive clones were extracted and sequenced.

VEGF₁₆₅ expression in 293T cell

Construction verified by sequencing was designated $pGC-FU-VEGF_{165}$. Then 293T cells were transfected with purified plasmid of $pGCFU-VEGF_{165}$ and pGC-FU which was harbouring a 3*tag fragment. The transfection followed the protocol of Lipo2000 kit and non-treatment

cells as control. For Western blotting approximately 2×10^6 cells were harvested and prepared total protein. Samples separated by polyacrylamide gel electrophoresis (PAGE), were blotted to polyvinylidene fluoride (PVDF) under 200 mA, 4°C for 2 hours. First antibody for GFP was added in hybridization solution and incubated for 2 hours. Then wash membrane with Tris-buffered saline containing 0.1% Tween-20 (TBST) and incubated with second antibody. Blot visualized by enhanced chemiluminescence (ECL) blotting system.

Lentivirus envelope and titer determination

Purified pGC-FU-VEGF₁₆₅, pHelper 1.0 and pHelper 2.0 plasmid transfected 293T cells were used to produce lentivirus. The supernatant of cell culture were harvested after 48-hour cultures, debris was dumped by 4000 g centrifugation for 10 minutes at 4°C. Then virus was purified with plus-20 kit (Millipore, USA) and storage at -80°C. The production of control virus enveloping pGC-FU followed the same protocol, meanwhile. For titer determination, virus was diluted 10 times in serum free culture consistently to prepare 8 concentrations of solution. 293T culture (App. 500 µl) planted in 24 wells plate were added with 10 µl virus solution. Cells were harvested after 4 days for qPCR test. Total RNA was extracted with TRIZOL and cDNA were obtained by M-MLV reaction. To determine the expression rate of GFP, SYBR-Green method was employed. The primers for GFP were upstream: 5'-TGCTTCAGCCGC-TACCC-3', downstream: 5'-AGTTCACCTTGATGC-CGTTC-3', amplified 211-496 bp fragment. And for actin were upstream: 5'-GTGGACATCCGCAAA-GAC-3', downstream: 5'-AAAGGGTGTAACGCAA-CTA-3', amplified 932-1233 bp fragment. Reaction followed the two-step protocol: 95.0°C for 15 seconds, 1 cycle, then 95.0°C for 5 seconds, 60.0°C for 30 seconds, 40 cycles. The titer of virus was then illustrated by mRNA expression rate.

Lentivirus infection and expression analysis

For rat ADSCs infection, lenti-VEGF₁₆₅ storage solution was diluted to appropriate concentration and added into cell culture. We used the lenti-GFP as the positive control and the no-transduced ADSCs as the negative control. These constructs were transduced into ADSCs overnight at a multiplicity of infection (MOI) of 20. After 48 hours, cells were examined under a microscope. For VEGF₁₆₅ expression analysis, we performed the enzyme-linked immunosorbent assay (ELISA) of the supernatant. And cells were harvested after 3 days to prepare total protein. Antibody for VEGF₁₆₅ was used in Western blotting, and procedure followed the steps described previously.¹⁰

Statistical analysis

Data were analyzed with SPSS 13.0 (SPSS Inc., IL, USA) and expressed as means \pm standard deviation. Student-*t* test was used to compare difference between two groups. Differences with *P* <0.05 were considered statistically

significant.

RESULTS

Vector construction

Entire VEGF₁₆₅ cDNA sequence was obtained by PCR reaction with three mutated fragments as template (Figure 1). *AgeI* digested DNA was linked to pGC-FU and produced pGC-FU-VEGF₁₆₅ vector, positive clones were examined by colony PCR test. Eight clones were examined in colony PCR test and DNA sequencing demonstrated that VEGF₁₆₅ cDNA was introduced into the GFP-fusion expression vector (Figure 2).



Figure 1. Fragment containing entire VEGF₁₆₅ cDNA sequence. F: Products of PCR reaction with three mutated fragments as template and VEGF₁₆₅-Age I-F, VEGF₁₆₅-Age I-R as primers.



Figure 2. Colony PCR tests of transformed DH5a. Samples 1–8: Products of PCR reaction with boiled DH5a cells as templates. The samples 1, 4, 8 were positive.

VEGF₁₆₅ expression in 293T cells

pGC-FU-VEGF₁₆₅ and pGC-FU vectors were transfected into 293T culture, after 24 hours more than 70% cells were observed GFP expression. Western blotting presented ~48 kD band for pGC-FU and a ~50 kD band for pGC-FU-VEGF₁₆₅ (Figure 3). Taking the IRES included in VEGF₁₆₅ sequence into consideration, the molecular weight of the fusion protein is 49 kD. Therefore the blot verified the expression of VEGF₁₆₅ under Ubi promoter driving in 293T cells.

Lentivirus envelope and titer determination

In quantitative test, 1 in 20 µl cDNA sample was applied



in real time PCR, thus read out value was 1/20 titer of virus solution. GFP expression rate illustrated by Table demonstrated that 10^{-4} (v/v) virus infected cells evidently expressed GFP. Therefore, titer of virus solution is $20/(10^{-4} \times 10^{-3}) = 2 \times 10^{8}$ TU/ml.

Letivirus infection and VEGF₁₆₅ expression in ADSCs

In the present study we chose rat ADSCs as candidates for transduction with VEGF₁₆₅. Transduction with GFP served as a negative control as well as for the determination of transduction efficiency, which was found to be greater than 95% (percentage of cells displaying green fluorescence). Afete 48-hour transduction, the VEGF₁₆₅ and the GFP transduced cells can show green fluorescence confirmed by immunofluorescence staining (Figure 4A), and there was no significant difference of the transduced ratio between VEGF₁₆₅ and the GFP transduced cells (P > 0.05). The Western blotting analyses confirmed VEGF₁₆₅ expression in VEGF₁₆₅-transduced cells but not in GFP-transduced cells (Figure 4B). And the ELISA analyses could detect out the density of VEGF was 850.86-1202.13 pg/ml (mean (923.00±31.22) pg/ml) in the supernatant of VEGF₁₆₅-transduced cells but not in the GFP-transduced cells (P < 0.001).

DISCUSSIONS

VEGF stimulates proliferation and migration of endothelial cells and plays a key role in cell division, basal layer hydrolysis, invasion and apoptosis, regenesis.¹¹ These adjustments performed considerable specificly, which effectively contribute to physiological or pathological procedure as embryonic development, repairing in trauma and collateral circulation formation etc.¹⁹ Within 5 variants of VEGF, VEGF₁₆₅ is the most widely distributed and with the strongest activity.¹¹ Therefore we constructed a VEGF₁₆₅ expression vector from a commercial clone by PCR mutation method. Sequence was blasted by Genebank online and confirmed consistently with registered transcripts NM 001025368 (NCBI). Because clinical application of VEGF is largely hindered by ephemerality and costliness, gene therapy is supposed to be optimal method in vascular regenesis research. Aligned with ADSC cells, the effects of VEGF₁₆₅ will fulfilled in target tissue treatment. Indeed, we construct a vector including Ubi promoter and GFP fusion to enhance the VEGF expression in stem cell and ease the expressing location. The Western blotting test

Samples	Ctas	Ctarr	Average Ctorn	∧ Ct	$\wedge Ct_{\alpha} = \wedge Ct_{\alpha}$
Samples	Ct Actin	Ct GFP	Average CtGFP		
Control	14.2	34.46	35.035	20.835	0
		35.61			
10 µl	14.67	17.62	17.610	2.940	17.895
		17.60			
1 µl	14.62	20.60	20.625	6.005	14.830
		20.65			
$10^{-1}\mu l$	14.89	23.91	24.080	9.190	11.645
		24.25			
10 ⁻² μl	14.38	26.96	26.975	12.595	8.240
		26.99			
10 ⁻³ μl	15.03	31.27	31.095	16.065	4.770
		30.92			
10 ⁻⁴ μl	14.67	33.22	33.000	18.330	2.505
		32.78			
$10^{-5} \mu l$	14.56	33.84	33.295	18.735	2.100
		32.75			





Figure 4. VEGF expressing in ADSCs in vitro. VEGF expression in cultured ADSCs was comfirmed by immunofluorescense (A–F) and the Western-blotting analyses (G). Approximately 95% ADSCs expressing VEGF confirmed by the immunofluorescent staining (Original magnification $\times 200$). A, D: the Lentivirus-GFP control; B, E: the Lentivirus-GFP-VEGF transferred

ADSCs; C, F: the negative ADSCs. The Western-blotting analyses (G) have also confirmed the expression of VEGF in ADSCs.

presents that GFP fused VEGF₁₆₅ expressed in 293T cells; thus, construction was verified at both DNA and protein level.

Moreover, produce lentivirus is crucial to obtain permanent VEGF expressing ADSC cells. Compared to traditional adenovirus, lentivirus takes advantages of wide infection range and long term expression endurance. As gene is integrated into host genomic DNA by lentivirus, it will not be dumped during division or differentiation. Besides, lentivirus is more protective than adenovirus in practice, as a pseudotype.^{20,21} We adopted three vectors envelope system and 293T cells to produce virus. Quantitative PCR test illustrated that titer of solution reached 2×10^8 TU/ml which is sufficient for ADSCs infection.

To obtain a therapeutic seed cells, efficient infection and stable expression of VEGF₁₆₅ is essential. One of the major disadvantages of adipose derived stem cell is that ADSCs are not a completely homogeneous cell population in addition to complicated isolating process. Tolerance of ADSCs to gene modification is high,

meanwhile, the cells possess high division potency.^{22,23} On the other side, the genotoxity of lentvirus is low, which supposes that ADSCs align with lentiviral expression vector would produce powerful therapeutic tool for related treatments. To our results, we successfully detected the VEGF₁₆₅ expression in the ADSCs but not in the control group, confirmed by the ELISA and Western blotting analyses. It illustrated that the VEGF₁₆₅ had successfully transfected the ADSCs and may suit to do the followed research.

In colclusion, we have constructed a VEGF₁₆₅-GFP fused expression lentivral vector and verified in 293T cells. Lentivirus was produced and titer is up to 2×10^8 TU/ml, determined by quantitative analysis of GFP mRNA. ADSCs were successfully infected and stable expression of VEGF₁₆₅ was confirmed by Western blotting. It suggested this cell may be widely introduced to vascular regenesis research, especially on ED treatment.

Acknowledgments: The authors gratefully acknowledge the valuable contribution of HUANG Jin-tao and WANG Na who helped in the preparation of laboratory experiments.

REFERENCES

- Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211-228.
- Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells--basic and clinical implications for novel cell-based therapies. Stem Cells 2007; 25: 818-827.
- 3. Meliga E, Strem BM, Duckers HJ, Serruys PW. Adipose-derived cells. Cell Transplant 2007; 16: 963-970.
- Zhang DZ, Gai LY, Liu HW, Jin QH, Huang JH, Zhu XY. Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction. Chin Med J 2007; 120: 300-307.
- Zhou YS, Liu YS, Tan JG. Is 1, 25-dihydroxyvitamin D3 an ideal substitute for dexamethasone for inducing osteogenic differentiation of human adipose tissue-derived stromal cells in vitro? Chin Med J 2006; 119: 1278-1286.
- Yang LY, Liu XM, Sun B, Hui GZ, Fei J, Guo LH. Adipose tissue-derived stromal cells express neuronal phenotypes. Chin Med J 2004; 117: 425-429.
- Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11382-11388.
- Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery *in vivo*. Nat Biotechnol 1997; 15: 871-875.
- Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A 1997; 94: 10319-10323.
- Lin G, Wang G, Liu G, Yang LJ, Chang LJ, Lue TF, et al. Treatment of type 1 diabetes with adipose tissue-derived stem cells expressing pancreatic duodenal homeobox 1. Stem Cells Dev 2009; 18: 1399-1406.
- 11. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109: 227-241.
- Ma L, Zhang Z, Wang X, Sun D, Zhou X, Chen A, et al. Screening of human vascular endothelial growth factor (VEGF) receptor Flt-1 domain and study on its biological activity. Sci China C Life Sci 2001; 44: 497-505.

- Xia JH, Xie AN, Zhang KL, Xu L, Zheng XY. The vascular endothelial growth factor expression and vascular regeneration in infarcted myocardium by skeletal muscle satellite cells. Chin Med J 2006; 119: 117-121.
- 14. Waller W, Lee J, Zhang F, Lineaweaver WC. Gene therapy in flap survival. Microsurgery 2004; 24: 168-173.
- 15. Jesmin S, Sakuma I, Salah-Eldin A, Nonomura K, Hattori Y, Kitabatake A. Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetes. J Mol Endocrinol 2003; 31: 401-418.
- Richardson D, Vinik A. Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep 2002; 2: 501-509.
- 17. Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int 2006; 97: 129-133.
- Deng CH, Sun XZ, Gao Y, Luo DS, Liu GH, Huang YP. An experimental study of the culture, isolation and biological characteristics of rat adipose tissue-derived stromal cells *in vitro*. Natl J Androl (Chin) 2008; 14: 99-105.
- Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999; 68: 830-836.
- 20. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. *In vivo* gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
- Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 2007; 15: 1947-1954.
- 22. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 2003; 174: 101-109.
- Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.

(Received April 17, 2011) Edited by HAO Xiu-yuan